Optimapharm, a clinical research organization (CRO) in Europe, has acquired the boutique Swiss CRO Denothex, strengthening its presence in European markets particularly in France, Germany, Switzerland, Spain and Italy.   Denothex manages clinical trials of all phases across Europe and Israel, with particular focus on biotechnology and medical devices in oncology.   By consolidating Denothex, Optimapharm says it is becoming one of the leading mid-size CRO companies in Europe. Optimapharm was esta...